Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABB C22
- Development stage
- Unknown
- Lead developer
- AB Biotek
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
ABB C22 is a postbiotic ingredient developed for the management of gastrointestinal disorders, including chronic constipation and diarrhea-associated inflammation. As a postbiotic, it consists of inanimate microorganisms and/or their components that confer a health benefit on the host. ABB C22 is characterized by its anti-inflammatory properties, demonstrated by its ability to significantly reduce fecal inflammatory biomarkers such as calprotectin and lactoferrin in clinical settings. It is often studied as a component of synbiotic formulations, such as ABB C24, where it is combined with the dextran prebiotic NextDext (ABB i5) to modulate the gut microbiome, increase the abundance of beneficial bacteria like Coprococcus spp., and reduce methanogenic bacteria like Methanobrevibacter smithii. Clinical trials have evaluated its efficacy in elderly populations with diarrhea and in individuals suffering from constipation, showing improvements in stool consistency and gut microbial diversity.
- Brand names
- ABB C22
Beyond the preview
Go deeper on ABB C22.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABB C22.